Key clinical point: GI side effects of peanut oral immunotherapy typically resolve.
Major finding: Six of seven biopsied patients showed near resolution at 2 years.
Study details: Mechanistic substudy of 20 patients enrolled in the phase 2 Peanut Oral Immunotherapy Safety, Efficacy and Discovery trial (POISED).
Disclosures: Dr. Wright reported receiving grants from the Arizona Biomedical Research Consortium and Phoenix Children’s Hospital Foundation. Coauthors reported grants from the National Institutes of Health and the Consortium for Food Allergy Research, as well as relationships with Aimmune Therapeutics, Regeneron Pharmaceuticals, Sanofi, CoFAR, DBV Technologies, Astellas, AnaptysBio, and Novartis.
Wright B et al. AAAAI, Session 2605, Abstract No. 259.